¡Ya estamos en ! Descubre más
ZYNE

Zynerba Pharmaceuticals, Inc

Excluida de cotización

ZYNE dejó de cotizar en bolsa el 10 de octubre de 2023.

 

Acerca de: Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Empleados: 27

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 0%
Neutral 0%
Negativo 0%

No hemos recibido artículos de noticias recientes sobre ZYNE.

Gráficos de precios implementados con Lightweight Charts™